Approval · Notice of Compliance 36596 · 2025
NEMLUVIO: Notice of Compliance 36596
Issued December 18, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36596
- Date
- December 18, 2025
- Company
- Galderma Canada Inc.Toronto, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
Medicinal ingredients
- NEMOLIZUMAB 30 MG per SYR
- NEMOLIZUMAB 30 MG per PEN